Navigation Links
Improved foam for varicose veins found to be safe in preliminary results from phase II trial

WINSTON-SALEM, N.C. A small group of patients with a common heart defect who were treated for varicose veins with an injectable microfoam experienced no neurological, visual or cardiac changes as a result of the treatment, according to preliminary results from a phase II trial. The results are being presented today (March 17) in Washington, D.C., at the annual scientific meeting of the Society of Interventional Radiology (SIR).

Injectable foams are usually made by mixing a sclerosant, an irritant that causes damage to the vein wall and subsequent scarring, with room air. Sclerosant foams have been a standard treatment since 1997 for spider veins and small varicose veins. Varisolve, a foam made with carbon dioxide, is relatively painless compared to other sclerosants, which can cause burning, said John D. Regan, M.D., clinical director of the Interventional Section in the Department of Radiology at Wake Forest University Baptist Medical Center.

Veins in the leg have valves that are designed to prevent blood from flowing backward as it returns to the heart. Varicose veins are caused by weakened valves (commonly in the great saphenous vein, the large vein running up the inner side of the leg) which allow blood to flow backward and pool in the veins in the leg. The resulting high pressure causes veins to expand like balloons and become tortuous or twisted. The latest treatments involve blocking the great saphenous vein (GSV) to prevent the backflow, called reflux. The Varisolve foam injection procedure is a less invasive alternative to surgical techniques and intravenous techniques that close the vein with radiofrequency ablation or laser energy.

Although any air-based foam carries a theoretical risk to the patient because of the insolubility of air in the blood, the risk is small, said Regan, the presenting author of the phase II trials preliminary results. We believe that the carbon-dioxide-based foam used in Varisolve will be totally safe due to the small size of the bubbles, the consistency of the foam and the solubility of carbon dioxide.

However, patients with a right-to-left shunt in their hearts a common, usually asymptomatic heart defect in about one-fourth of the population are at increased risk of foam bubbles crossing the shunt and going to the brain or heart without being filtered in the lungs, according to Regan. These patients, the subjects of the study, are continuously monitored by transcranial Doppler ultrasound of the brain before, during and after the procedure. They also undergo magnetic resonance imaging (MRI) of the brain, visual testing, neurological examinations and examinations for changes in cardiac markers in the blood.

During the procedure, a small catheter is placed in the malfunctioning GSV, and the Varisolve foam is injected into the vein. The GSV is compressed in the groin to trap the foam in the leg and additional foam is injected. The patients leg is then put in a compression dressing and stocking, and the patient is able to get up and walk immediately.

In more than 90 percent of the 28 patients studied so far (13 at Wake Forest Baptist) at six research sites across the country, tiny bubbles have been detected in the blood during the procedure. However, no neurological, visual or cardiac changes were observed in the monitoring. The study will continue until a total of 50 patients have been treated and monitored.


Contact: Robin Brantley
Wake Forest University Baptist Medical Center

Related biology news :

1. Improved e-jet printing provides higher resolution and more versatility
2. In-vitro fertilization improved with 3-D/4-D-guided embryo transfer and new placement target
3. UCR researchers awarded nearly $1.7M to develop improved cowpea varieties
4. Physician-scientist urges improved drug regulation to ensure heart safety of non-heart drugs
5. Key to out-of-control immune response in lung injury found
6. Natural chemical found in broccoli helps combat skin blistering disease
7. Balzan Foundation announces 2007 winners
8. Keck Foundation funds study of biological interactions with nanomaterials
9. Yu receives research funding from the Wallace H. Coulter Foundation
10. New dinosaur species found in Montana
11. PETA awards $120,000 to Duluth Foundation for advancing non-animal tests
Post Your Comments:
(Date:11/12/2015)... Nov. 12, 2015  A golden retriever that stayed ... dystrophy (DMD) has provided a new lead for treating ... the Broad Institute of MIT and Harvard and the ... . Cell, pinpoints a protective ... the disease,s effects. The Boston Children,s lab of ...
(Date:11/10/2015)... , Nov. 10, 2015  In this ... the basis of product, type, application, disease ... in this report are consumables, services, software. ... are safety biomarkers, efficacy biomarkers, and validation ... report are diagnostics development, drug discovery and ...
(Date:11/4/2015)... York , November 4, 2015 ... a new market report published by Transparency Market Research "Home ... Growth, Trends and Forecast 2015 - 2022", the global home ... US$ 30.3 bn by 2022. The market is estimated ... forecast period from 2015 to 2022. Rising security needs ...
Breaking Biology News(10 mins):
(Date:11/24/2015)...  PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI ) today ... and chief executive officer, will present at the 27 th ... New York City . The presentation will be ... at 9:30 a.m. EST. and go ... least 15 minutes prior to the presentation to allow for ...
(Date:11/24/2015)... (PRWEB) , ... November 24, 2015 , ... Whitehouse Laboratories ... Laboratory. The new stand-alone facility will be strictly dedicated to basic USP 61, ... and existing clients the chance to have complete chemistry and micro testing performed by ...
(Date:11/23/2015)... with a certain type of lung nodule visible on lung ... cancer than men with similar nodules, according to a new ... the Radiological Society of North America ... Lung nodules are small masses of tissue in the lungs ... appearance on CT. Solid nodules are dense, and they obscure ...
(Date:11/23/2015)... Nov. 23, 2015 China Cord Blood Corporation ... leading provider of cord blood collection, laboratory testing, hematopoietic ... announced its preliminary unaudited financial results for the second ... September 30, 2015. --> ... , Revenues for the second quarter of fiscal 2016 ...
Breaking Biology Technology: